Join
Live feed
·
PRReleasevia Quantisnow
Lantheus Holdings Inc. logo

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
LNTH· Lantheus Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LNTH (Lantheus Holdings Inc.) and more on Quantisnow.